What Side Effects Does Published Retatrutide Trial Data Document?

Because Retatrutide activates the same GLP-1 receptor pathway shared by the entire incretin drug class, its reported adverse-event profile in trial literature overlaps substantially with Semaglutide and Tirzepatide — gastrointestinal effects (nausea, vomiting, diarrhea, constipation) were the most commonly reported category across the trial population, generally described as dose-dependent and most pronounced during dose-escalation phases.

The Phase 2 trial publication also reported the glucagon-receptor-associated changes the compound is specifically studied for, including effects on heart rate and hepatic markers, as part of its full safety data set alongside the efficacy outcomes.

This summary reflects what the cited published trial literature reports and is provided for research background only — it is not a complete safety profile, is not medical advice, and REVIVE LAB UAE does not provide dosing or administration guidance for any product it sells.